作为协议的一部分，这家制药巨头将获得Conduit的普通股，以及包括预付款、里程碑和版税在内的再许可收入。Conduit has reached a licensing agreement with Astrazeneca for three experimental therapies.
Biopharmaceutical company Conduit Pharmaceuticals (CDT.US) announced on Thursday that it has reached a licensing agreement with Astrazeneca (AZN.US) for three experimental therapies. At the time of writing, Conduit rose 130.79% before the market opened, to $0.38.
Under the terms of the agreement, Astrazeneca will grant exclusive licenses to three Phase 2 candidate products to Conduit, located in San Diego, California, namely AZD1656, AZD5658 and AZD5904.
As part of the agreement, the pharmaceutical giant will receive Conduit's common stock, as well as re-licensing income including prepayments, milestones and royalties.
Licensing for AZD1656 and AZD5658 is targeted for all human indications, while licensing for AZD5904 covers idiopathic male infertility. Conduit plans to conduct Phase 2 trials of AZD1656 and AZD5658 this year, with a focus on autoimmune diseases.
